40045-50-9

Usage

Uses

SU 3327 is a JNK inhibitor.

InChI:InChI=1/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8)

Upstream product

• 3034-48-8 2-bromo-5-nitro-1,3-thiazole 
• 2349-67-9 2-Amino-5-mercapto-1,3,4-thiadiazole 

Downstream Products

• 1064665-02-6 4-fluoro-N-(5-(5-nitrothiazol-2-ylthio)-1,3,4-thiadiazol-2-yl)benzamide 

Relevant academic research and scientific papers

Nitrothiazole derivatives and hydrochloride thereof Application of sulfate in preparation of medicine for treating livestock intestinal infection

The invention relates to the technical field of pharmaceutical chemistry, in particular to application of nitrothiazole derivatives and hydrochloride and sulfate thereof in preparation of drugs for treating livestock intestinal infections. Compared with chickens, pigs, sheep and deer bacterial enteritis, the synthesized nitrothiazole derivative has high biological activity, the treatment effect is remarkable, and the application value is high.

Application of thio-thiadiazole containing nitrothiazole compound in prevention and treatment of agricultural plant diseases

The invention relates to the field of medicinal chemistry, and discloses an application of 5-((5-nitrothiazole-2-yl)sulfo)-1,3,4-thiadiazole compounds H-1 to H-8 in resisting phytopathogens. Bioactivity tests find that the compound has potential inhibitory activity on eight agricultural diseases such as rhizoctonia solani, sclerotinia sclerotiorum, fusarium graminearum, botrytis cinerea, cotton fusarium oxysporum, magnaporthe grisea, citrus canker and phytophthora parasitica, and part of the compounds have high inhibitory activity. The compound is simple to prepare, raw materials are cheap andeasy to obtain, and the compound is expected to be developed into a novel bacteriostatic agent.

Design, synthesis, and structure-activity relationship of substrate competitive, selective, and in vivo active triazole and thiadiazole inhibitors of the c-jun n-terminal kinase

We report comprehensive structure-activity relationship studies on a novel series of c-Jun N-terminal kinase (JNK) inhibitors. The compounds are substrate competitive inhibitors that bind to the docking site of the kinase. The reported medicinal chemistry

Pharmaceutical compositions and methods for modulating signal transduction

The present invention relates to organic molecules capable of inhibiting protein tyrosine phosphatase activity. The invention further relates to the use of such molecules to modulate or regulate signal transduction by inhibiting protein tyrosine phosphatase activity. Finally, the invention relates to the use of such molecules to treat various disease states including diabetes mellitus.